JLABS | Road to first-in-human trials for small molecules

Are you a biotech startup preparing for your first-in-human clinical trials? Join Johnson & Johnson’s upcoming programme to gain essential insights into the Clinical Trial Application (CTA) process for small molecules, including Antisense Oligonucleotides (ASOs), siRNA, and small peptides.

This event offers expert guidance on:

• Preclinical development strategies: Preparing your asset for clinical trials, covering toxicity and pharmacokinetics.
• Chemistry, Manufacturing & Controls (CMC): Ensuring your API and formulations meet regulatory standards.
• Clinical trial design: Crafting trials to demonstrate safety and efficacy, with practical tips on patient recruitment.
• Regulatory strategies: Navigating the European CTA requirements.

This event is tailored for startups entering first-in-human trials but also welcomes early innovators, entrepreneurs, and stakeholders supporting these ventures.

Seize the opportunity to strengthen your clinical trial strategy!

Find more informatio here.